Canada · Delayed Price · Currency is CAD TelyRx Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 143% year-over-year to $22.7M, driven by repeat customers now making up nearly 70% of revenue. Investments in marketing, a new website, and expanded operations support future growth, with gross margin rising to 57% and record prescription volumes achieved.
-
A scalable, cash-pay pharmacy platform disrupts the $98B market by delivering 450+ medications quickly and transparently, achieving $43M annual revenue with strong repeat customer growth and expanding margins. Regulatory barriers protect its model, while tech and customer experience investments boost retention and lifetime value.
-
A digital pharmacy platform has achieved rapid growth by offering over 450 everyday medications with same-day delivery, transparent pricing, and no insurance required, targeting the $98 billion cash-pay market. With $43 million in 2025 revenue, strong repeat customer rates, and scalable operations, it is positioned for continued expansion and margin improvement.
-
Q1 2026 revenue surged 180% year-over-year to $19.4M, with prescriptions filled up 188%. Gross margin improved to 55%, and management expects to achieve over $100M in 2026 revenue, with positive EBITDA for the year.